Neurotoxicity of biologically targeted agents in pediatric cancer trials

about

Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors Age-Dependent Cellular and Behavioral Deficits Induced by Molecularly Targeted Drugs Are Reversible.

P2860

Q26825655-70019F0E-2A6E-4500-9390-0E116F104259 Q53429907-AFC79271-DC55-465B-A180-F7F0104DE5B8

P2860

Neurotoxicity of biologically targeted agents in pediatric cancer trials

Item

http://www.wikidata.org/entity/Q36766221

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@ast

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@en

type

Item

label

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@ast

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@en

prefLabel

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@ast

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@en

P1476

Neurotoxicity of biologically targeted agents in pediatric cancer trials

@en

P2093

Amulya A Nageswara Rao

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Wells

http://www.w3.org/2001/XMLSchema#string

Roger J Packer

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of vorinostat in acute myeloid leukemia

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Safety of anticoagulation use and bevacizumab in patients with glioma.

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

P304

212-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PEDIATRNEUROL.2012.02.006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joseph Scafidi

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223972246

http://www.w3.org/2001/XMLSchema#string

P698

22490765

http://www.w3.org/2001/XMLSchema#string

P921

neurotoxicity

P932

3626408

http://www.w3.org/2001/XMLSchema#string

Neurotoxicity of biologically targeted agents in pediatric cancer trials

about

P2860

P2860

Neurotoxicity of biologically targeted agents in pediatric cancer trials

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932